Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robbert G van der Most

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Human Vaccines & Immunotherapeutics|June 1, 2019
Role and plasticity of Th1 and Th17 responses in immunity to <i>Staphylococcus aureus</i>Alessandra Ferraro, Sofia M Buonocore, Philippe Auquier, et al.
Clinical and Vaccine Immunology : CVI|April 28, 2017
Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled TrialsRobbert G van der Most, Frédéric Clément, Julie Willekens, et al.
Journal of Virology|December 23, 2004
Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and diseaseJolanda D F de Groot-Mijnes, Jessica M van Dun, Robbert G van der Most, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 15, 2006
Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotidesRobbert G van der Most, Robyn Himbeck, Simon Aarons, et al.
Vaccine|March 1, 2005
Fast track selection of immunogens for novel vaccines through visualisation of the early onset of the B-cell responseAntonio Scibelli, Robbert G van der Most, Johan A Turkstra, et al.
Cancer Research|September 6, 2005
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapySteve Broomfield, Andrew Currie, Robbert G van der Most, et al.
Science Translational Medicine|August 8, 2014
Seeking help: B cells adapting to flu variabilityRobbert G van der Most, François P Roman, Bruce Innis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 23, 2008
Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumorsAndrew J Currie, Robbert G van der Most, Steve A Broomfield, et al.
Vaccine|May 15, 2007
Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challengeAdriaan F G Antonis, Robbert G van der Most, Yasemin Suezer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulationAndrew J Currie, Amy Prosser, Alison McDonnell, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Human Vaccines & Immunotherapeutics|June 1, 2019
Role and plasticity of Th1 and Th17 responses in immunity to <i>Staphylococcus aureus</i>Alessandra Ferraro, Sofia M Buonocore, Philippe Auquier, et al.
Clinical and Vaccine Immunology : CVI|April 28, 2017
Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled TrialsRobbert G van der Most, Frédéric Clément, Julie Willekens, et al.
Journal of Virology|December 23, 2004
Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and diseaseJolanda D F de Groot-Mijnes, Jessica M van Dun, Robbert G van der Most, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 15, 2006
Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotidesRobbert G van der Most, Robyn Himbeck, Simon Aarons, et al.
Vaccine|March 1, 2005
Fast track selection of immunogens for novel vaccines through visualisation of the early onset of the B-cell responseAntonio Scibelli, Robbert G van der Most, Johan A Turkstra, et al.
Cancer Research|September 6, 2005
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapySteve Broomfield, Andrew Currie, Robbert G van der Most, et al.
Science Translational Medicine|August 8, 2014
Seeking help: B cells adapting to flu variabilityRobbert G van der Most, François P Roman, Bruce Innis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 23, 2008
Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumorsAndrew J Currie, Robbert G van der Most, Steve A Broomfield, et al.
Vaccine|May 15, 2007
Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challengeAdriaan F G Antonis, Robbert G van der Most, Yasemin Suezer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2009
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulationAndrew J Currie, Amy Prosser, Alison McDonnell, et al.
Pageof 4